Tag: Dana-Farber Cancer Institute

Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

Cyclacel Pharmaceuticals (Nasdaq:CYCC, Nasdaq:CYCCP) a biopharmaceutical company developing innovative medicines based on cancer biology, announced the initiation of a Phase...

Precipio Strengthens Patent Portfolio with Expanded Kit Claims for its Liquid Biopsy Enabling DNA Mutation Enrichment Technology

Specialty cancer diagnostics company Precipio (NASDAQ:PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT WITH REFERENCE BLOCKING...